June 2, 2024 11:09 PM EDTUpdated 07:01 AM
R&D
Pharma
Manufacturing

Ex­clu­sive: Iso­tope short­age forces pause of Bris­tol My­ers Phase 3 ra­dio­phar­ma­ceu­ti­cal tri­al

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

The de­vel­op­ment of the lead drug be­hind Bris­tol My­ers Squibb’s re­cent $4.1 bil­lion ac­qui­si­tion of Rayze­Bio has hit de­lays, be­cause of sup­ply is­sues of a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times